A clinical trial at the Jacobs School of Medicine and Biomedical Sciences at UB is seeking patients aged 18-65 with Type 1 diabetes whose hemoglobin A1C (HbA1C), a measure of sugar in the blood, is between 7% and 10%.
The 52-week study will determine whether patients with Type 1 diabetes benefit when their insulin therapy is supplemented with two drugs designed to treat Type 2 diabetes — semaglutide and dapaglifozin — or with semaglutide alone.
The primary endpoint will be a reduction in patients’ mean baseline HbA1c, which is considered optimal in Type 1 diabetes when under 7%. Currently, less than 20% of patients with Type 1 diabetes have HbA1c of under 7%.
Join the study and more –> Buffalo.edu
